3 results
This study will evaluate the efficacy and safety of multiple therapies that are selected using somatic alterations and potential predictive biomarkers identified via NGS assays in patients with solid tumors.
The pivotal Phase III NETTER-1 study showed that Lutathera with best supportive care (30mg octreotide long-acting) provided a significant increase in PFS to patients with progressive midgut carcinoid tumors (at enrollment) compared to patients…
Primary objectives:• To evaluate safety of repeat doses of [18F]AlF-RESCA-IL2.• To evaluate tumour uptake of [18F]AlF-RESCA-IL2 in patients with cancer.• To evaluate whole body distribution of [18F]AlF-RESCA-IL2 in cancer patients.Secondary…